Tarsus Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TARS research report →
Range $89 – $116
Price Chart
About the company
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease.
- CEO
- Bobak R. Azamian
- IPO
- 2020
- Employees
- 370
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on TARS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.60B
- P/E
- -5.00
- Fwd P/E
- 164.03
- PEG
- 0.00
- P/S
- 5.49
- P/B
- 33.89
- EV/EBITDA
- -5.41
- Div Yield
- 0.00%
- Gross Margin
- 93.21%
- Op Margin
- -102.04%
- Net Margin
- -102.93%
- ROE
- -245.72%
- ROIC
- -250.05%
Latest fiscal year · YoY change
- Revenue
- $451.36M+146.7%
- Gross Profit
- $420.68M+147.3%
- Op Income
- $-70,969,000
- Net Income
- $-66,418,000+42.5%
- EPS
- $-1.59+48.2%
- OCF Growth
- +85.0%
- FCF Growth
- +73.6%
- 52W High
- $91.53
- 52W Low
- $53.89
- 50D MA
- $74.22
- 200D MA
- $68.22
- Beta
- 0.54
- RSI (14)
- 48
- Avg Volume
- 869.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tarsus delivered another record quarter as XDEMVY sales surged, guidance was raised, and management said the launch still has room to grow while pipeline programs advance toward 2027-2029 milestones.· November 3, 2026
- XDEMVY net product sales were a record $194.6 million in Q3, up nearly 64% year over year, with weekly prescriptions at an all-time high.
- Full-year 2026 XDEMVY sales guidance was raised to $715 million-$730 million, reflecting stronger patient demand, deeper ECP utilization, and better DTC returns.
- Gross margin remained about 93%, and cash and cash equivalents were about $310 million at quarter end.
- Management said retreatments were about 20% of prescriptions in Q3 and expects that to settle in the low 20% range over time.
- The company outlined multiple pipeline milestones, including TP-04/TP-05 top-line data in 1H27, IRX-101 Phase III initiation in 1H27, and gildeuretinol top-line data in 2H29.
Q3 XDEMVY net product sales were $194.6 million, up nearly 64% year over year. Gross margin was approximately 93%. SG&A was $168 million, R&D was $44 million, and cash and cash equivalents were approximately $310 million. Acquired IPR&D charges totaled $632 million, including $81 million for iRenix and $551 million for Alkeus. For full-year 2026, Tarsus raised XDEMVY sales guidance to $715 million-$730 million, expects gross margin to remain about 93%, SG&A at $605 million-$620 million, and R&D at $140 million-$155 million.
Bobby Azamian framed the quarter as evidence that Tarsus has built something bigger than a single-product company, citing more than 1 million bottles dispensed, more than $1 billion in cumulative net product sales, and a pipeline aimed at five potential new medicines over five years. His tone was upbeat and expansive, emphasizing that XDEMVY is still early in its growth curve and that the company is trying to build the next leader in eye care. He highlighted the company’s category-creation playbook, acquisitions, and pipeline breadth across Stargardt disease, ocular rosacea, Lyme disease prevention, and an ocular antiseptic.
Jeff Farrow emphasized disciplined capital allocation, saying the company is directing spend toward the highest-return commercial opportunities and development milestones. He cited Q3 net product sales of $194.6 million, gross margin of about 93%, SG&A of $168 million, R&D of $44 million, and quarter-end cash of about $310 million. On guidance, he raised 2026 XDEMVY sales to $715 million-$730 million and said gross margin should stay around 93%, while SG&A and R&D guidance reflect higher DTC, variable costs, and integration expenses. He also reiterated that gross-to-net discounting should remain in the 43% to 45% range next quarter and into 2027.
Analysts focused on whether XDEMVY growth can sustain into 2027 and beyond, the role of DTC versus organic screening, retreatment durability, gross-to-net assumptions, competitive risk, and pipeline development paths. Management said DTC remains important but is becoming more efficient, with spending likely still in the $80 million to $95 million range next year, and that 43% to 45% gross-to-net remains a good assumption. On concerns that XDEMVY may approach saturation, management argued this is a new category with no good analog, pointed to 25 million Americans with DB, and said physicians are still expanding patient types and prescribing more broadly. On Stargardt, management said the FDA endorsed the Northstar study design and endpoints, while keeping open the option of another Phase III trial if needed.
The call showed strong momentum in the core XDEMVY launch, with record quarterly sales, rising weekly prescriptions, and raised full-year guidance. Management believes there is still meaningful runway because awareness, prescriber adoption, and retreatment are all growing, while the company sees a large untreated market and a favorable safety/efficacy profile.
The main risks discussed were whether XDEMVY growth will eventually slow as the category matures, whether gross-to-net pressure or DTC efficiency changes could weigh on results, and whether competition in Demodex blepharitis could emerge. The pipeline also remains early and capital-intensive, with major readouts and Phase III starts not expected until 2027 or later, and management acknowledged some regulatory and development uncertainty, especially around Stargardt and future trial requirements.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.6%
- Shares Outstanding
- 49.31M
- Float Shares
- 46.65M
of shares held by institutions
270 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 3.87M | ▲ 10.30K |
| Deep Track Capital, LP | 3.67M | ▲ 66.77K |
| Rtw Investments, LP | 3.36M | ▲ 11.03K |
| Fmr LLC | 3.27M | ▲ 2.60M |
| Jupiter Topco LLC | 2.81M | ▲ 2.81M |
| Paradigm Biocapital Advisors LP | 2.78M | ▲ 213.50K |
| Vanguard Group Inc | 2.40M | ▲ 127.47K |
| Janus Henderson Group Ltd. | 2.24M | ▲ 310.64K |
| Vanguard Capital Management LLC | 1.88M | ▲ 85.94K |
| Morgan Stanley | 1.71M | ▼ 116.43K |
| Jennison Associates LLC | 1.66M | ▼ 48.47K |
| Tang Capital Management LLC | 1.57M | ▲ 379.64K |
Held by 265 ETFs
Biggest fund positions in TARS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Azamian Bobak R. | sell | 10,000 |
| Nov 3, 26 | Clase Neera | other | 10,587 |
| Nov 3, 26 | Clase Neera | other | 6,678 |
| Nov 1, 26 | Clase Neera | other | 0 |
| Nov 1, 26 | Clase Neera | other | 0 |
| Nov 1, 26 | Clase Neera | other | 0 |
| Nov 1, 26 | Clase Neera | other | 0 |
| Nov 1, 26 | Clase Neera | other | 0 |
| Nov 1, 26 | Clase Neera | other | 0 |
| Nov 1, 26 | Clase Neera | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TARS coverage
Recent articles, reports, and earnings notes.
No research on TARS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TARS report →8,971 Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Commonwealth Equity Services LLC
defenseworld.net · Nov 16
Tarsus to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 5
Tarsus Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Nov 3
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 3
Tarsus Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 3
How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%
zacks.com · Nov 2
My 'Eye' Is On Tarsus Pharmaceuticals
seekingalpha.com · Nov 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.